In two Phase III trials, Bayer's VEGF Trap-Eye drug, also called Eylea, met its primary endpoint in treating diabetic macular edema, the company said. The firm co-develops the medication with Regeneron, which plans to seek U.S. marketing approval this year for the treatment of diabetic macular edema.

Related Summaries